Institutional Ownership
Sionna Therapeutics Inc
CUSIP 829401108COMSIONQ1 2026
13D / 13G Filings
10
Schedule 13D/13G on record
Beneficial Filers
8
Distinct reporting persons
Largest Stake
23.7%
Max % of class reported
Institutional Holders
117
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
10 filings · latest Nov 7, 2025
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Nov 7, 2025 | Ra Capital Management, L.P. | 13D/A | 22.6% | — | SEC |
| 2 | Oct 20, 2025 | Atlas Venture Fund Xi, L.P. | 13D/A | 5.4% | — | SEC |
| 3 | Jul 30, 2025 | Jpmorgan Chase &Amp; Co. | 13G | 5.0% | 2.22M | SEC |
| 4 | Jun 16, 2025 | Qatar Investment Authority | 13G | 5.0% | 2.21M | SEC |
| 5 | Feb 18, 2025 | Tpg Gp A, LLC | 13D | 15.2% | — | SEC |
| 6 | Feb 18, 2025 | Atlas Venture Fund Xi, L.P. | 13D | 6.5% | — | SEC |
| 7 | Feb 18, 2025 | Ra Capital Management, L.P. | 13D | 23.7% | — | SEC |
| 8 | Feb 18, 2025 | Enavate Sciences Gp, LLC | 13D | 5.6% | — | SEC |
| 9 | Feb 14, 2025 | Viking Global Investors LP | 13G | 6.7% | 2.95M | SEC |
| 10 | Feb 13, 2025 | Orbimed Advisors LLC | 13D | 8.4% | — | SEC |
Top Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Ra Capital Management, L.P. | 9.91M | $397.09M |
| 2 | Tpg Gp A, LLC | 6.49M | $260.38M |
| 3 | Orbimed Advisors LLC | 3.53M | $141.55M |
| 4 | Viking Global Investors LP | 3.20M | $128.09M |
| 5 | Atlas Venture Life Science Advisors, LLC | 3.00M | $120.09M |
| 6 | Enavate Sciences Gp, LLC | 2.48M | $99.34M |
| 7 | Jennison Associates LLC | 1.45M | $58.18M |
| 8 | Jpmorgan Chase & Co | 1.47M | $53.71M |
| 9 | Blackrock, Inc. | 1.30M | $51.95M |
| 10 | Citadel Advisors LLC | 1.17M | $46.78M |